23 May 2024
An exciting milestone in our pursuit to make CAR T-cell therapy a standard of care in New Zealand, the Environmental Protection Authority NZ has approved use of chimeric antigen receptor (CAR) T-cells in our phase 2 clinical trial with BioOra.
As a trial of this kind had never been done before in New Zealand, our team has put significant time and effort into working with national regulatory bodies such as the EPA and MedSafe to navigate and establish the necessary regulatory pathways to bring CAR T-cell technology to New Zealand.
In doing so, we have opened doors for similar life-saving cell therapy trials to be undertaken here in the future - whether our own or others.
Related articles
Kjesten Wiig: bringing life-changing treatments to life
27 February 2025
Read more
Malaghan CAR T-cell cancer therapy trial expands to Christchurch and Auckland
24 February 2025
Read more
Cancer Research Trust grant to improve CAR T-cell therapy
12 February 2025
Read more
Community partnerships: Zephyr Consulting empowering emerging scientific talent
18 November 2024
Read more
CAR T-cell therapy, the battle of the blood cells
26 September 2024
Read more
Phase 2 clinical trial underway to confirm effectiveness and safety of NZ’s first CAR T-cell cancer therapy
23 July 2024
Read more